FINANCINGS
Ablynx NV said it completed the placement of $111.3 million in senior unsecured convertible bonds due May 2020.
Agenus Inc. priced a public offering of 11 million common shares with expected proceeds of $69.3 million.
Auris Medical Holding AG priced a public offering for approximately $25 million.
Circassia Pharmaceuticals plc is raising $432 million in a placing and open offer to fund the acquisition of Aerocrine AB and Prosonix Ltd.
Celyad SA filed with the SEC for a U.S. IPO seeking to raise up to $115 million through a combination of proceeds from the offering and a concurrent private placement outside the U.S.
Cortendo AB has raised $33.2 million in a private placement.
Dicerna Pharmaceuticals Inc. priced a public offering expecting to raise $48.8 million.
Momenta Pharmaceuticals Inc. priced a public offering seeking to raise $137.75 million.
Psioxus Ltd. has raised $38.5 million in a series C round.
Regenxbio Inc. completed a heavily oversubscribed $70.5 million series D financing.
Rxi Pharmaceuticals Corp. filed a registration statement with the SEC to offer up to $25 million in common stock and warrants.
DEALS
Ablynx NV signed a research collaboration with Sanofi SA unit Genzyme to investigate nanobodies against a target that plays an important role in multiple sclerosis.
Achillion Pharmaceuticals Inc. signed a potential $1.1 billion deal with Johnson & Johnson unit Janssen Pharmaceuticals Inc.
Alcyone Lifesciences Inc. and Dnatrix Inc. said they have inked an exclusive clinical collaboration deal.
Areva Med and Radiomedix Inc. entered an agreement to co-develop a treatment for neuroendocrine tumors using targeted alpha therapy with lead-212.
Argen-x NV and Leo Pharma A/S entered an alliance, potentially worth more than $116 million, for the development of antibody drugs for inflammatory skin conditions.
Biontech AG signed a deal with Genmab A/S to develop bispecific antibodies for cancer immunotherapy.
Boehringer Ingelheim GmbH is exercising an option to in-license PXS4728A, a dual semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 inhibitor, from Pharmaxis Ltd.
Diaxonhit SA has granted Felicitex Therapeutics Inc. a license for a series of compounds for the development of therapeutics against quiescent cancer cells.
Endo International plc is paying $8.05 billion to acquire Par Pharmaceutical Holdings Inc.
Ipsen SA inked an agreement to acquire Octreopharm Sciences GmbH.
Lannett Co. Inc. signed an agreement to acquire Silarx Pharmaceuticals Inc., a manufacturer of liquid generic pharmaceutical products.
OMT Therapeutics Inc. has partnered with the California Institute of Technology, which will use its Unirat platform for the generation of nanobodies against HIV-1.
Sorrento Therapeutics Inc. signed a potential $1.3 billion-plus deal with Nantworks Inc.
. . . AND MORE
Medicago Inc. said it plans to build a new $245 million production complex in Quebec City.
Neostem Inc. will receive a $17.7 million grant from the California Institute for Regenerative Medicine to support work on its treatment for patients with metastatic melanoma.
Oncosec Medical Inc. received approval to conduct a 1-for-20 reverse stock split.
Pernix Therapeutics Holdings Inc. said the FDA approved Treximet for use in pediatric patients for the acute treatment of migraine.